GLP3 60mg

This is a triple agonist that targets the GLP-1, GIP, and glucagon receptors, making it the most advanced and potent appetite suppressant and metabolic drug developed to date. It adds a third layer by stimulating the glucagon receptor, which further enhances energy expenditure and fat oxidation. In clinical trials, R3TA has delivered the most dramatic bodyweight reductions ever seen in pharmaceutical research, with some patients losing over 20% of their total bodyweight in under a year.